Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novartis AG Common Stock (NY:NVS)

112.12 +1.41 (+1.27%)
Streaming Delayed Price Updated: 11:55 AM EDT, May 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
45 46 Next >
Pediatric Drugs Market Giants Spending Is Going to Boom : Pfizer, Bayer, Abbott Laboratories, Merck
NJ New Jersey, USA -- (SBWIRE) -- 04/10/2023 -- Latest Study on Industrial Growth of Pediatric Drugs Market 2022-2027. A detailed study accumulated to offer Latest insights about acute features of the... 
Via SBWire
Cryoport Supports Clinical Trials And Commercial Therapies Across The High-Growth BioTech Industry: Is Its Current Stock Price An Opportunity?
The global biotechnology industry was worth $859 billion in 2022, and it is predicted to reach $1.6 trillion by 2030, growing at a compound annual growth rate (CAGR) of 8.7% over the forecast period.  
Via Benzinga
Novartis Shares Leap On Positive Clinical Trial Data
Swiss pharmaceutical giant Novartis leaped 5.11% in the past week following news that its Kisqali breast-cancer treatment cut the probability of relapse. 
Via MarketBeat
6 Questions With Rocket Pharma's CEO On World Health Day: How The Biotech Is 'Changing The Narrative'
Rocket Pharma (NASDAQ: RCKT) CEO Gaurav Shah is on a mission to "change the narrative" when it comes to rare diseases. 
Via Benzinga
Novartis AG (NYSE: NVS) Records 52-Week High Thursday Morning
Via Investor Brand Network
FDA Approves Pharming's Immune Disorder Drug, As First APDS Therapy
Via Benzinga
7 Very Undervalued Penny Stocks to Buy in April 2023
Undervalued penny stocks present investors who are very bullish on the near-term future with a high-risk, high-reward option. 
Via InvestorPlace
The Byzantine Adderall Shortage Puts Teva And Others In The Hot Seat
Millions of people are scrambling to get their ADHD medication. Here's why. 
Via Investor's Business Daily
Stock Market Rallies On Micron, Alibaba, Lululemon, Ebbing Bank Fears: Weekly Review
The stock market rallied on ebbing bank fears and positive news from Micron, Alibaba and Lululemon Athletica. 
Via Investor's Business Daily
What Bear Market? These 2 Winning Stocks Are Still Worth Buying.
These two pharma stocks are rock-solid picks in any kind of market. 
Via The Motley Fool
How Is The Market Feeling About Novartis?
Via Benzinga
FDA Approves Novartis' Tafinlar + Mekinist For Pediatric Brain Cancer With Certain Mutations
Via Benzinga
Why Jounce Therapeutics Shares Are Trading Higher By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Crown ElectroKinetics Corp. (NASDAQ: CRKN) shares jumped 59.6% to $0.2513. Crown Electrokinetics said it has entered into an agreement with a leading infrastructure solutions provider. 
Via Benzinga
Elon Musk-Led Neuralink Seeks Human Trial Collaborators, Credit Suisse May Face Disciplinary Action, First Citizens Takeover Silicon Valley Bank: Today's Top Stories
Benzinga 
Via Benzinga
Novartis Surges As It Goes After Eli Lilly's Second Biggest Moneymaker
The battle in early-stage breast cancer is heating up as Novartis enters the ring. 
Via Investor's Business Daily
Why Novartis Shares Are Trading Higher Premarket Today
Novartis AG (NYSE: NVS) shares are trading higher in the premarket session after its breast cancer drug showed clinical benefit in early-stage breast cancer. 
Via Benzinga
First Republic Bank, KeyCorp And Other Big Stocks Moving Higher In Monday's Pre-Market Session
U.S. stock futures traded higher this morning. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
New research project aims to set standardized approach to lipoprotein(a) management
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
2 Biotech Stocks That Could Make You Richer
One is a well-established, large-cap drugmaker, while the other is still making a name for itself in the industry. 
Via The Motley Fool
Two Big Pharma Companies Bow Out Of Neurology Drug Partnerships With Sangamo
Two big-name partners have walked away from partnerships with Sangamo Therapeutics Inc (NASDAQ: SGMO) over a few days. 
Via Benzinga
Novartis Reveals Long-Term Data Of Atrophy Gene Therapy Exhibiting Sustained Durability Of Up To 7.5 Years
Via Benzinga
Elon Musk Frets As Microsoft Axes AI Ethics Team, Richard Branson's Virgin Orbit Stops Ops, Credit Suisse To Borrow Up To $54B: Today's Top Stories
Benzinga 
Via Benzinga
Novartis' Prostate Cancer Therapy Hit By Supply Crunch, Seeks To Ramp Up Production To Ease Supply Issues
Last week the FDA said Novartis AG's (NYSE: NVS) Pluvicto is short in supply due to manufacturing and delivery issues.  Pluvicto is a radiopharmaceutical medication used for prostate-specific membrane... 
Via Benzinga
Rise in Biotech Innovations Generating Hope as Pancreatic Cancer Survival Rates Climb
FN Media Group Presents USA News Group News Commentary Vancouver, BC – March 14, 2023 – USA News Group – Optimism is on the rise as the American Cancer Society is reporting that the five-year survival... 
Via FinancialNewsMedia
Exposures Product Safety
3 High Dividend Stocks With Attractive Total Return Potential
In the current economic environment, it is crucial for investors to prioritize quality, reliable dividend stocks and high total returns. 
Via InvestorPlace
Cell Therapy Has Shown Near Miraculous Remission Rates In Cancer Patients, But The Growing Industry Relies On This Company – A Uniquely Positioned Ticker In The Weeds?
Cell Therapy Has Shown Near Miraculous Remission Rates In Cancer Patients, But The Growing Industry Relies On This Company – A Uniquely Positioned Ticker In The Weeds? 
Via News Direct
Topics Economy
Exposures Supply Chain
Cell Therapy Has Shown Near Miraculous Remission Rates In Cancer Patients, But The Growing Industry Relies On This Company – A Uniquely Positioned Ticker In The Weeds?
By David Willey, Benzinga 
Via TheNewswire.com
Topics Economy
Exposures Supply Chain
Cell Therapy Has Shown Near Miraculous Remission Rates In Cancer Patients, But The Growing Industry Relies On This Company – A Uniquely Positioned Ticker In The Weeds?
Cryoport Inc. (NASDAQ: CYRX) provides the life sciences industry with comprehensive supply chain solutions to support vital therapeutics. 
Via Benzinga
4 AI Stocks That Are Revolutionizing Healthcare
With the growing use of AI in healthcare, it has led to a number of stocks that are focused on this industry. 
Via InvestorPlace
This Company Is Focused on Treg-Enhancing Therapies - Could This Be Medicine's Next Frontier?
Texas-based biotech company, Coya Therapeutics (NASDAQ: COYA), is positioning itself as a leader in a promising area of the medical field. 
Via Benzinga
< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
45 46 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.